21 June 2017
Bonesupport has announced the outcome of the offering of newly issued shares in the Company (the “Offering”) and its listing on Nasdaq Stockholm. The Offering attracted strong interest among Swedish and international investors and the Offering was oversubscribed several times.
The final price of the Offering has been set at SEK 29 per share, corresponding to a market capitalization of SEK 1,416 million based on the total number of outstanding shares in Bonesupport following the Offering, providing the Over-allotment option (defined below) is fully utilized.
Bonesupport develops injectable, bioceramic bone graft substitutes with the capability of eluting drugs into the bone void. Cerament G and other products are part of Bonesupport’s Cerament technology platform.
Stage Capital backed the business through a venture stage investment backed by NBG Technology LP.
“I am delighted with the strong support we have generated from both new investors, including Swedbank Robur, and our existing investors. The backing of these high quality investors highlights the significant potential of Bonesupport’s CERAMENT™ products,” commented Richard Davies, CEO of Bonesupport. “Our IPO will provide us with the funds we need to execute our strategy of driving sales in both the US and Europe, generating additional clinical data to enhance the competitive positioning of our products and completing the FORTIFY study, which is key to gaining US approval for CERAMENT G. Our stronger financial position will also allow us to invest in our pipeline of new products that are designed to promote bone growth. This strategy provides the foundation for our 2020 financial targets and will allow us to generate significant value for our shareholders.”